An extensive analysis shows scant evidence that ketamine or other NMDA receptor agonists reduce chronic noncancer pain but ...

The U.S. Food and Drug Administration has approved the ketamine product, KETARx, for use in surgical pain management.

By Lori Solomon HealthDay ReporterMONDAY, Aug. 18, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...

A sweeping review of 67 trials has cast doubt on the use of ketamine and similar NMDA receptor antagonists for chronic pain relief. While ketamine is frequently prescribed off-label for conditions ...

The off-label use of ketamine to treat chronic pain is not supported by scientific evidence, a new Cochrane review has found.

Researchers cautioned that the existing evidence base is too poor to draw any solid conclusions on whether ketamine can help ...

A Cochrane review assessed ketamine and other NMDA receptor antagonists for chronic non-cancer pain. The evidence was low to very low certainty, showing no clear pain relief and potential adverse ...

A major Cochrane review found no convincing evidence that ketamine or similar NMDA-blocking drugs improve chronic non-cancer ...

Ketamine is regularly used for the treatment of chronic pain, but a new report shows there is no clear evidence of its benefit.The off-label use of ...

A strong anesthetic ‘Ketamine’ is normally used in hospital procedures. Ketamine is also used for short-term pain management in hospitals. It works by blocking a brain signal ...